In the latest trading session, Edwards Lifesciences (EW) closed at $217.52, marking a +1.34% move from the previous day. The stock outpaced the S&P 500’s daily gain of 0.58%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 1.66%.

Heading into today, shares of the medical device maker had gained 23.98% over the past month, outpacing the Medical sector’s gain of 5.64% and the S&P 500’s gain of 3.15% in that time.

EW will be looking to display strength as it nears its next earnings release, which is expected to be April 23, 2020. The company is expected to report EPS of $1.38, up 4.55% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.07 billion, up 7.89% from the year-ago period.

EW’s full-year Zacks Consensus Estimates are calling for earnings of $5.40 per share and revenue of $4.40 billion. These results would represent year-over-year changes of -3.05% and +1.23%, respectively.

Any recent changes to analyst estimates for EW should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.